
    
      The patient population will include postmenopausal women with hormone-receptor positive
      primary breast cancer scheduled for adjuvant upfront endocrine treatment with anastrozole or
      following two to three years of tamoxifen treatment ("switch") according to the current SmPC
      (Appendix C). Patients will have taken anastrozole for at least three months and not more
      than six months before the start of the study.
    
  